ETView Medical, Ltd., and State of the Art (SOTA) Medical Products, Inc., executed distribution agreement
The agreement enables SOTA to market ETView's VivaSight™ platform in New York, New Jersey, Pennsylvania and Delaware.
February 2, 2012, Tel Aviv, Israel‐ETView Medical Ltd. (TASE: ETVW) announced today that it has entered into a distribution agreement with State of the Art (SOTA) Medical Products, Inc. The agreement enables SOTA to market ETView's VivaSight™ platform (previously known as TVT™), combining an airway ventilation tube with integrated, continuous, high‐resolution airway imaging for patient airway control and lung isolation capability in New York, New Jersey, Pennsylvania, and Delaware for a period of 3 years. Other terms were not announced.
William Edelman, CEO of ETView Medical, commented, “We are excited to add SOTA to our expanding distributor network.” Mr. Edelman continued, “VivaSight™ is currently being distributed across Europe and the United States. VivaSight™ provides best‐in‐class airway management solutions for sophisticated thoracic surgical procedures requiring lung isolation.”
On December 12, 2011, ETView announced that the company has successfully completed filing of a Pre‐Marketing Notification Application (510(k)) with the US Food and Drug Administration (FDA) for the VIVASIGHT™‐DL Airway Management System. VivaSight™‐DL1 is a proprietary, single‐use, disposable medical device, consisting of a dual‐lumen airway ventilation tube with an integrated, continuous, high‐resolution video airway imaging system permitting airway control and lung isolation during certain surgical procedures. Lung isolation is employed to provide one‐lung ventilation in patients undergoing thoracic, cardiac, vascular, or esophageal Surgeries.2 During lung isolation, temporary visualization of the patient airway is achieved with a fiberoptic bronchoscope while the patient is ventilated and the target lung isolated. Intraoperative surgical maneuvers often require repeated imaging and partial blocking of the airway to maintain lung isolation.3 It is estimated that over 1.9 million lung isolation procedures are conducted worldwide annually,4 accounting for over $250mm in single‐use medical disposables.5 ETView has pioneered development of the VivaSight™ platform (previously known as TVT™), combining an airway ventilation tube with integrated, continuous, highresolution airway imaging for patient airway control and lung isolation capability (eliminating the need for fiberoptic bronchoscope6 imaging during these procedures). Additional pre‐market regulatory filings in Europe and Asia are anticipated during 2012.
About State of the Art Medical Products, Inc.
According to information provided to the company State of the Art (SOTA) Medical Products, Inc. is a specialty surgical products sales and distribution company, based in Cedar Grove, New Jersey. Founded in 1982, the company’s mission has been to bring new high technology products to market. In today’s healthcare environment, each product must provide a benefit to physicians, hospitals and patients. SOTA Medical Products, Inc. services the following states: New York, New Jersey, Pennsylvania, and Delaware. Visit www.etview.com for additional
About ETView, Medical, Ltd.
ETView Medical Ltd. (TASE: ETVW) has successfully combined airway management with continuous direct airway visualization for medical professionals. ETView's patented VivaSight™‐SL, a single‐use, disposable medical device consisting of a single‐lumen ventilation tube with an integrated, continuous, high‐resolution video imaging system, is currently sold in Europe, Israel, and the US to overcome current limitations and associated adverse surgical events during lung isolation surgeries.7 It is estimated that over 1.9 million lung isolation procedures are conducted worldwide annually,8 accounting for over $250mm in single‐use
The Company estimations in this press release, including those estimations regarding the Company's predicted scope of business, constitute forward‐looking statements, as such term is defined under the Israeli Securities Law (5728‐1968), and there is no certainty that such estimations shall materialize. The Company's estimations are based on business assumptions, prior experience, and professional data. Due to various factors, foreseen and unforeseen, including, but not limited to, changes in market trends, competition, global or local economic conditions, and amendments of regulation, such estimations may not materialize in whole or in part, or materialize in a substantially different manner than anticipated by the Company.
(1) Patent Pending
(2) Principles and Practices of Anesthesia for Thoracic Surgery. P. Singer (ed.) 2011
(3) Anesthesia & Analgesia. 2009;108:1097–101
(4) National Health Statistics Reports Number 29, October 26, 2010
(5) Company estimates on file
(6) Minerva Anestesiol. 2009;75(Suppl 1):1‐4.
(7) Anesthesiology. 2006;105:471‐477.
(8) National Health Statistics Reports Number 29, October 26, 2010
(9) Company estimates on file